Navigation Links
Cytochroma Appoints Dr. John Cunningham to its Scientific Advisory Board
Date:10/15/2009

MARKHAM, ON, Oct. 15 /PRNewswire/ - Cytochroma today announced that it has appointed John Cunningham, CVO, BM BCh, DM, FRCP, to the Company's Scientific Advisory Board.

Dr. Cunningham is Professor of Nephrology at the UCL Medical School, London and Consultant Nephrologist at the Royal Free Hospital, London. His early training was at Cambridge and Oxford Universities, with postgraduate training in The University of London and Washington University School of Medicine, St. Louis, USA. In 2005, he was appointed to the position of Physician to HM the Queen. Dr. Cunningham has extensive experience in the fields of hypertension, renal stone disease, acute and chronic kidney disease, renal transplantation and dialysis, and metabolic bone disease. He has published in excess of 100 peer reviewed scientific articles, is a visiting professor to various universities in Europe, Australia, and the United States, a member of numerous international expert panels and working groups, and a national and international lecturer.

"We are delighted and honored that Dr. Cunningham has agreed to advise Cytochroma on its efforts to develop new drugs for secondary hyperparathyroidism in chronic kidney disease patients," said Charles W. Bishop, Ph.D., President and Chief Executive Officer of Cytochroma. "Dr. Cunningham's wealth of knowledge and clinical experience will be invaluable as we move our products through mid- and late-stage clinical trials."

    Other members of Cytochroma's Scientific Advisory Board include:

    -   Geoff Block, MD - Director of Clinical Research, Denver Nephrology

    -   David Allen Bushinsky, MD - Professor of Medicine and of Pharmacology
        and Physiology, University of Rochester School of Medicine, and
        Chief, Nephrology Division, University of Rochester Medical Center

    -   Russell Chesney, MD - Le Bonheur Professor and Chair, Department of
        Pediatrics, University of Tennessee Health Science Center

    -   Bess Dawson-Hughes, MD - Professor of Medicine, Tufts University
        School of Medicine, and Senior Scientist and Director, Bone
        Metabolism Laboratory Jean Mayer USDA Human Nutrition Research Center
        on Aging at Tufts University

    -   Glenville Jones, PhD - Head of Biochemistry Department, Professor of
        Biochemistry & Medicine, Queen's University, Kingston, Ontario

    -   Kevin Martin, MD - Director of Research, Division of Nephrology, St.
        Louis University School of Medicine

    -   L. Darryl Quarles, MD - Vice Chairman for Research, Department of
        Internal Medicine, and Director, The Kidney Institute and Division of
        Nephrology at the University of Kansas Medical Center

    -   Isidro Salusky, MD - Professor of Pediatric Medicine, David Geffen
        School of Medicine, and Director of Clinical Research Center, UCLA
        School of Medicine

    -   Stuart Sprague, MD - Professor of Medicine, Feinburg School of
        Medicine, and Chief, Division of Nephrology & Hypertension, Evanston
        Northwestern Healthcare, Northwestern University

    About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company specializes in developing new vitamin D therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma has three lead product candidates in clinical development for CKD patients: CTA018 Injection and CTAP201 Injection are being developed for the treatment of SHPT in stage 5 CKD, while CTAP101 Capsules are being developed for the treatment of vitamin D insufficiency and associated SHPT in stage 3 and 4 CKD. CTA018 Injection is being developed in partnership with Mitsubishi Tanabe Pharma Corporation for the U.S. and Asian markets, and Cytochroma retains co-promotion rights for this product in the U.S. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in CKD patients.

SOURCE Cytochroma


'/>"/>
SOURCE Cytochroma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cytochroma announces appointment of Ulrik Spork to Board of Directors
2. Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance
3. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
4. Cytochroma Closes $45 Million Series C Financing
5. Cytochroma Appoints R. Richard Wieland II As CFO
6. Cytochroma opens U.S. headquarters in Illinois
7. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
8. Sundia Appoints Charles D. Maher as Senior Vice President of Sales and Marketing
9. CalciMedica Appoints Evelyn Graham to its Board of Directors
10. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
11. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... ... 2016 , ... STACS DNA Inc., the sample tracking software company, today announced ... has joined STACS DNA as a Field Application Specialist. , “I am thrilled ... COO of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays ...
(Date:6/23/2016)... 2016  Blueprint Bio, a company dedicated to identifying, ... community, has closed its Series A funding round, according ... "We have received a commitment from Forentis Fund ... to meet our current goals," stated Matthew Nunez ... to complete validation on the current projects in our ...
Breaking Biology Technology:
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):